Fibrogen announces topline results from phase 3 zephyrus-1 study of pamrevlumab for the treatment of idiopathic pulmonary fibrosis

-  study did not meet the primary endpoint -  pamrevlumab was generally safe and well tolerated -  zephyrus-2 phase 3 study will be discontinued -  company to implement plan to extend cash runway into 2026
FGEN Ratings Summary
FGEN Quant Ranking